- Patisiran, sold
under the
brand name
Onpattro, is a
medication used for the
treatment of
polyneuropathy in
people with
hereditary transthyretin-mediated...
- drug
Onpattro, a gene
therapy that was
approved (August 2018) by the FDA to
treat hereditary amyloid transthyretin (hATTR) amyloidosis.
Onpattro is the...
-
Using LNPs for drug
delivery was
first approved in 2018 for the
siRNA drug
Onpattro. LNPs
became more
widely known late in 2020, as some COVID-19 vaccines...
-
temporary relief.
Before Onpattro was released, the
treatment options for
hATTR were limited.
After the
approval of
Onpattro, FDA
awarded Alnylam with...
-
amyloidotic polyneuropathy (FAP). In
August 2018, with its
commercial name
Onpattro,
patisiran received the U.S.
regulatory approval to
treat polyneuropathy...
-
Pharmaceuticals and
licensed to
Akcea Therapeutics.
Patisiran (sold
under Onpattro) was
developed by
Alnylam Pharmaceuticals, and also
approved for use in...
- the sale of part of its
royalty interest on ****ure
global net
sales of
ONPATTRO, an RNA
interference therapeutic currently sold by
Alnylam Pharmaceuticals...
-
phospholipase 2G6-****ociated
neurodegeneration (PLAN). The FDA
granted Patisiran (
Onpattro)
orphan drug
status and
breakthrough therapy designation due to its novel...
-
delivery system was in 2018, when the
agency approved the
first siRNA drug,
Onpattro.
Encapsulating the mRNA
molecule in
lipid nanoparticles was a critical...
- 2091985. hdl:1959.4/unsworks_80922. ISSN 1744-2818. PMID 35875890. "LABEL:
ONPATTRO-
patisiran injection,
lipid complex".
Daily Med. 10 May 2021. "Drug Approval...
